Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 615 participants.
Also called NCT01763827
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 615 participants
- Sponsor
- Registry
-
NCT01763827
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Canada, Denmark, France, South Africa, South Korea, Taiwan, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01763827. Randomized; quadruple masking; primary purpose treatment. Start 2013-01-21 (actual); primary completion 2013-10-10 (actual). Results posted on 2015-12-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
- Acronym
- MENDEL-2
- Condition
- Hyperlipidemia
- Intervention (Biological)
- Evolocumab
- Intervention (Drug)
- Ezetimibe
- Intervention (Biological)
- Placebo to Evolocumab
- Intervention (Other)
- Placebo to Ezetimibe
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01763827- Content hash
3d2582303ff3b26e30b4fc31d9e9fb3db7b8b8b7bf89f1657491959d48c03e18